<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03267186</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-38934</org_study_id>
    <secondary_id>NCI-2017-00125</secondary_id>
    <secondary_id>IRB-38934</secondary_id>
    <secondary_id>BMT302</secondary_id>
    <nct_id>NCT03267186</nct_id>
  </id_info>
  <brief_title>Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant</brief_title>
  <official_title>A Phase 2 Study of Ibrutinib Maintenance After Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrew Rezvani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well ibrutinib works in preventing acute leukemia in patients&#xD;
      after reduced-intensity conditioning and stem cell transplant. Ibrutinib may stop the growth&#xD;
      of tumor cells by blocking some of the enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To reduce the incidence of relapse at 18 months after reduced-intensity conditioning (RIC)&#xD;
      and allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML),&#xD;
      acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML) in blast crisis from a&#xD;
      historical baseline of 45% to 25%, using ibrutinib maintenance therapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To study the incidence and severity of post-transplant complications in subjects receiving&#xD;
      ibrutinib maintenance after allogeneic HCT.&#xD;
&#xD;
      II. To study the incidence of infectious complications in subjects receiving maintenance&#xD;
      ibrutinib after allogeneic HCT.&#xD;
&#xD;
      III. To study the impact of ibrutinib maintenance on minimal residual disease after RIC and&#xD;
      allogeneic HCT.&#xD;
&#xD;
      IV. To study the impact of maintenance ibrutinib on immune reconstitution and alloreactivity&#xD;
      after allogeneic HCT, specifically on Th1/ Th2 polarization, T follicular cell number, T and&#xD;
      B cell repertoire, serum immunoglobulin levels, and alloantibody formation.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Beginning 60-90 days after allogeneic HCT, patients receive ibrutinib orally (PO) once daily&#xD;
      (QD) for up to 18 months post-transplant in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 12, 2017</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of relapsed leukemia</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Incidence of relapsed leukemia defined as &gt; 5% leukemic blasts detected in bone marrow or peripheral blood. Participants will also be considered to have relapsed leukemia if they receive any active treatment for progressive leukemia after allogeneic HCT, even if they have &lt; 5% leukemic blasts. Withdrawal of immunosuppression alone is not considered an active treatment for progressive disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute GVHD grades II-IV and III-IV</measure>
    <time_frame>At 180 days</time_frame>
    <description>Incidence of acute GVHD grades II-IV and III-IV will be evaluated according following criteria.&#xD;
Stage of Acute GvHD was assessed as follows.&#xD;
Stage 1: Skin: rash &lt; 25% of skin. Liver: bilirubin 2 to 3 mg/dL. Gut: diarrhea &gt;500 mL/day or upper-gut symptoms with positive histology&#xD;
Stage 2: Skin: rash 25 to 50% of skin. Liver: bilirubin 3 to 6 mg/dL. Gut: diarrhea &gt;1000 mL/day.&#xD;
Stage 3: Skin: rash &gt; 50% of skin. Liver: bilirubin 6 to 15 mg/dL. Gut: diarrhea &gt; 1500 mL/day.&#xD;
Stage 4: Skin: generalized erythroderma with bulla formation. Liver: bilirubin &gt; 15 mg/dL. Gut: diarrhea &gt; 2500 mL/day or severe abdominal pain with or without ileus&#xD;
Grade of Acute GvHD was determined as follows.&#xD;
Grade 1: Stage 1-2 Skin + No Liver stage + No Gut stage&#xD;
Grade 2: Stage 3 Skin OR Stage 1 Liver or Stage 1 Gut&#xD;
Grade 3: No Skin stage + Stage 2 to 3 Liver Stage 2 to 4 Gut&#xD;
Grade 4: Stage 4 Skin + or Stage 2 to 3 Liver + No Gut stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD</measure>
    <time_frame>At 18 months</time_frame>
    <description>Assessment of chronic GvHD will be performed using the 2015 NIH consensus criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of detectable minimal residual disease</measure>
    <time_frame>At 1 year</time_frame>
    <description>Incidence of detectable minimal residual disease will be assessed using high-throughput sequencing (ClonoSEQ) and high-sensitivity flow cytometry. Minimal residual disease will be considered present if &gt; 1 x 10^-6 leukemic clones are detected by ClonoSEQ, or if any aberrant blasts matching the original leukemic immunophenotype are detected by high-sensitivity flow cytometry.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Acute Biphenotypic Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Hematopoietic Cell Transplantation Recipient</condition>
  <arm_group>
    <arm_group_label>Prevention (ibrutinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning 60-90 days after allogeneic HCT, patients receive ibrutinib PO QD for up to 18 months post-transplant in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Prevention (ibrutinib)</arm_group_label>
    <other_name>BTK Inhibitor PCI-32765</other_name>
    <other_name>CRA-032765</other_name>
    <other_name>Imbruvica</other_name>
    <other_name>PCI-32765</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Prevention (ibrutinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  INCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT)&#xD;
&#xD;
          -  Diagnosis of acute myeloid leukemia (AML), acute biphenotypic leukemia, or acute&#xD;
             lymphoblastic leukemia (ALL); CML transformed to blast crisis is eligible&#xD;
&#xD;
          -  Planned allogeneic HCT using fludarabine phosphate (FLU)/melphalan hydrochloride (MEL)&#xD;
             or FLU/busulfan (BU) conditioning&#xD;
&#xD;
          -  Planned graft versus host disease (GVHD) prophylaxis consisting of tacrolimus&#xD;
             (TAC)/methotrexate (MTX) or TAC/sirolimus (SRL)&#xD;
&#xD;
          -  Human leukocyte antigen (HLA) identical sibling donor, HLA matched unrelated donor, or&#xD;
             donor mismatched at 1 HLA allele or antigen&#xD;
&#xD;
          -  Less than or equal to 5% blasts on bone marrow examination within 60 days of starting&#xD;
             conditioning&#xD;
&#xD;
          -  Age &gt;= 18 years and =&lt; 70 years&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Subjects will be eligible if their planned conditioning regimen for allogeneic HCT&#xD;
             consists of one of the two following standard reduced intensity conditioning regimens:&#xD;
&#xD;
               -  FLU/MEL: fludarabine phosphate (fludarabine) 120 to 180 mg/m^2; melphalan&#xD;
                  hydrochloride (melphalan) =&lt; 150 mg/m^2&#xD;
&#xD;
               -  FLU/BU: fludarabine 120 to 180 mg/m^2; busulfan =&lt; 8 mg/kg orally or =&lt; 6.4 mg/kg&#xD;
                  intravenously&#xD;
&#xD;
          -  Subjects will be eligible if their planned post grafting immunosuppression consists of&#xD;
             one of the two following regimens:&#xD;
&#xD;
               -  TAC/MTX: tacrolimus (oral or intravenous) and intravenous methotrexate&#xD;
                  administered according to institutional standard practice.&#xD;
&#xD;
               -  TAC/SRL: tacrolimus (oral or intravenous) and oral sirolimus, administered&#xD;
                  according to institutional standards of care&#xD;
&#xD;
          -  INCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION)&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of =&lt; 2&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt; 0.75 x 10^9/L&#xD;
&#xD;
          -  Platelet count &gt; 50 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin &gt; 8.0 g/dL without transfusion or growth factor support for at least 7 days&#xD;
             prior to screening (with the exception of pegylated granulocyte-colony stimulating&#xD;
             factor [G-CSF] and darbopoietin, which require at least 14 days of abstinence prior to&#xD;
             screening)&#xD;
&#xD;
          -  Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 3.0 x&#xD;
             upper limit of normal&#xD;
&#xD;
          -  Estimated creatinine clearance &gt;= 30 mL/min via Cockroft-Gault formula&#xD;
&#xD;
          -  Bilirubin =&lt; 1.5 x upper limit of normal (unless elevated bilirubin is due to&#xD;
             Gilbert's syndrome or of non-hepatic origin)&#xD;
&#xD;
          -  Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin&#xD;
             time (PTT) (activated partial thromboplastin time [aPTT]) =&lt; 1.5 x upper limit of&#xD;
             normal&#xD;
&#xD;
          -  Female subjects who are of non-reproductive potential (ie, post-menopausal by history&#xD;
             - no menses for &gt;= 1 year; OR history of hysterectomy; OR history of bilateral tubal&#xD;
             ligation; OR history of bilateral oophorectomy); female subjects of childbearing&#xD;
             potential must have a negative serum pregnancy test upon screening&#xD;
&#xD;
          -  Male and female subjects who agree to use both a highly effective method of birth&#xD;
             control (eg, implants, injectables, combined oral contraceptives, some intrauterine&#xD;
             devices [IUDs], sexual abstinence, or sterilized partner) and a barrier method (eg,&#xD;
             condoms, vaginal ring, sponge, etc) during the period of therapy and for 30 days after&#xD;
             the last dose of study drug for females and 90 days after the last dose of the study&#xD;
             drug for males&#xD;
&#xD;
          -  Between day +60 and day +90 after allogeneic HCT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Active involvement of the central&#xD;
             nervous system with malignancy (previous central nervous system [CNS] involvement is&#xD;
             allowed if clearance of CNS disease has been documented prior to enrollment)&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Pregnant or breastfeeding&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Karnofsky performance status &lt; 60%&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Active leukemia (&gt; 5% leukemic&#xD;
             blasts in peripheral blood or bone marrow)&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Non-hematologic malignancy with a&#xD;
             life expectancy of &lt; 5 years&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Known history of human&#xD;
             immunodeficiency virus (HIV) or active hepatitis C virus (HCV) or hepatitis B virus&#xD;
             (HBV) infection; subjects who are positive for hepatitis B core antibody or hepatitis&#xD;
             B surface antigen must have a negative polymerase chain reaction (PCR) result before&#xD;
             enrollment; those who are PCR positive will be excluded&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Known bleeding disorders (eg, von&#xD;
             Willebrand's disease) or hemophilia&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): History of other malignancies,&#xD;
             except:&#xD;
&#xD;
               -  Malignancy treated with curative intent and with no known active disease present&#xD;
                  for &gt;= 3 years before the first dose of study drug and felt to be at low risk for&#xD;
                  recurrence by treating physician&#xD;
&#xD;
               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease Adequately treated carcinoma in situ without evidence of disease&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Active and uncontrolled acute&#xD;
             GVHD grades III or IV&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Use of secondary therapy for&#xD;
             acute GVHD at any time (defined as any systemic therapy intended to treat acute GVHD&#xD;
             besides corticosteroids)&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Requirement for&#xD;
             anticoagulation with warfarin or other vitamin K antagonists (concomitant use of other&#xD;
             anticoagulants is permitted)&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Relapsed leukemia (&gt; 5%&#xD;
             leukemic blasts in peripheral blood or bone marrow after allogeneic HCT)&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Karnofsky performance status &lt;&#xD;
             60%&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Chemotherapy =&lt; 21 days prior&#xD;
             to first administration of study treatment and/or monoclonal antibody =&lt; 6 weeks prior&#xD;
             to first administration of study treatment&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Vaccinated with live,&#xD;
             attenuated vaccines within 4 weeks of first dose of study drug&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Currently active, clinically&#xD;
             significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4&#xD;
             congestive heart failure as defined by the New York Heart Association Functional&#xD;
             Classification; or a history of myocardial infarction, unstable angina, or acute&#xD;
             coronary syndrome within 6 months prior to randomization&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): History of stroke or&#xD;
             intracranial hemorrhage within 6 months prior to screening&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Any life threatening illness,&#xD;
             medical condition, or organ system dysfunction that, in the investigator's opinion,&#xD;
             could compromise the subject's safety or put the study outcomes at undue risk&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Major surgery within 4 weeks&#xD;
             of first dose of study drug&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Any uncontrolled active&#xD;
             systemic infection&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Unresolved toxicities from&#xD;
             prior anti cancer therapy, defined as having not resolved to Common Terminology&#xD;
             Criteria for Adverse Event (CTCAE, version 4), grade =&lt; 1, or to the levels dictated&#xD;
             in the inclusion/exclusion criteria with the exception of alopecia&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Unable to swallow capsules or&#xD;
             malabsorption syndrome, disease significantly affecting gastrointestinal function, or&#xD;
             resection of the stomach or small bowel, symptomatic inflammatory bowel disease or&#xD;
             ulcerative colitis, or partial or complete bowel obstruction&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Requires treatment with a&#xD;
             strong cytochrome P450 (CYP) 3A4/5 inhibitor&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Unwilling or unable to&#xD;
             participate in all required study evaluations and procedures&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Unable to understand the&#xD;
             purpose and risks of the study and to provide a signed and dated informed consent form&#xD;
             (ICF) and authorization to use protected health information (in accordance with&#xD;
             national and local subject privacy regulations)&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Currently active, clinically&#xD;
             significant hepatic impairment (Child-Pugh class B or C)&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Lactating or pregnant&#xD;
&#xD;
          -  EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Uncontrolled cardiac&#xD;
             arrhythmias&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Rezvani</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 28, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Andrew Rezvani</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 8, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03267186/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

